Penn researchers have developed a platform that emulates human bone marrow’s native environment. This breakthrough addresses ...

Frontline treatment with Tevimbra plus irinotecan, paclitaxel, oxaliplatin and 5-FU/leucovorin had promising efficacy and ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Blood flow and other mechanical factors influence the delivery of cancer cells to specific organs ... site within an organ 31 — has a high or low probability of growing. It has been recognized ...

Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the therapy itself caused any type of secondary cancer in the modified T cells, ...

Malignant T-cell transformation ... in the peripheral blood (29.34%) on day 74 after infusion but not at any previous time points. This clone was detected at low abundance (<2%) in the duodenal ...

Hidden within our bones, marrow sustains life by producing billions of blood cells daily, from oxygen-carrying red cells to immune-boosting white cells. This vital function is often disrupted in ...